Skip to main content Accessibility help
×
Hostname: page-component-788cddb947-w95db Total loading time: 0 Render date: 2024-10-09T05:03:36.013Z Has data issue: false hasContentIssue false

Levetiracetam

Published online by Cambridge University Press:  01 June 2018

Philip N. Patsalos
Affiliation:
UCL Institute for Neurology
Erik K. St Louis
Affiliation:
Mayo Clinic
Get access

Summary

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Aiguabella, M, Falip, M, Villanueva, V, de la Peña, P, Molins, A, Garcia-Morales, I, Saiz, RA, Pardo, J, Tortosa, D, Sansa, G, Miró, J. Efficacy of intravenous levetiracetam as an add-on treatment in status epilepticus: a multicentric observational study. Seizure 2011; 20: 6064.CrossRefGoogle ScholarPubMed
Alsaadi, T, El Hammasi, K, Shahrour, TM. Does pyridoxine control behavioral symptoms in adult patients treated with levetiracetam? Case series from UAE. Epilepsy and Behavior Case Reports 2015; 4: 9495.CrossRefGoogle ScholarPubMed
Ben-Menachem, E, Falter, U; for the European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000; 41: 12761283.CrossRefGoogle ScholarPubMed
Beniczky, SA, Viken, J, Jensen, LT, Andersen, NB. Bone mineral density in adult patients treated with various antiepileptic drugs. Seizure 2012; 21: 471472.CrossRefGoogle ScholarPubMed
Berkovic, SF, Knowlton, RC, Leroy, RF, Schiemann, J, Falter, U; Levetiracetam N01057 Study Group. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 2007; 69: 17511760.CrossRefGoogle ScholarPubMed
Brodie, MJ, Perucca, E, Ryvlin, P, Ben-Menachem, E, Meencke, HJ; Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007; 68: 402408.CrossRefGoogle ScholarPubMed
Crest, C, Dupont, S, Leguern, E, Adam, C, Baulac, M. Levetiracetam in progressive myoclonic epilepsy: an exploratory study in 9 patients. Neurology 2004; 62: 640643.CrossRefGoogle ScholarPubMed
Fattore, C, Boniver, C, Capovilla, G, Cerminara, C, Citterio, A, Coppola, G, Costa, P, Darra, F, Vecchi, M, Perucca, E. A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. Epilepsia 2011; 52: 802809.CrossRefGoogle ScholarPubMed
Hernandez-Diaz, S, Smith, CR, Shen, A, Mittendorf, R, Hauser, WA, Yerby, M, Holmes, LB. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012; 78: 16921699.CrossRefGoogle ScholarPubMed
Johannessen Landmark, C, Patsalos, PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Reviews in Neurotherapeutics 2010; 10: 119140.CrossRefGoogle ScholarPubMed
Kossoff, EH, Bergey, GK, Freeman, JM, Vining, EP. Levetiracetam psychosis in children with epilepsy. Epilepsia 2001; 42: 16111613.CrossRefGoogle ScholarPubMed
Krauss, GL, Bergin, MB, Kramer, RE, Cho, YW, Reich, SG. Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology 2001; 56: 411412.CrossRefGoogle ScholarPubMed
Major, P, Greenberg, E, Khan, A, Thiele, EA. Pyridoxine supplementation for the treatment of levetiracetam-induced behavior side effects in children: preliminary results. Epilepsy and Behavior 2008; 13: 557559.CrossRefGoogle ScholarPubMed
Mawhinney, E, Craig, J, Morrow, J, Russell, A, Henry Smighson, W, Parsons, L, Morrison, PJ, Liggan, B, Irwin, B, Delanty, N, Hunt, SJ. Levetiracetam in pregnancy. Result from the UK and Ireland epilepsy and pregnancy registers. Neurology 2013; 80: 400405.CrossRefGoogle ScholarPubMed
Patsalos, PN. Antiepileptic drug interactions: a clinical guide, 3rd edition. Springer, London, UK; 2016.CrossRefGoogle Scholar
Patsalos, PN. Levetiracetam: pharmacology and therapeutics in the treatment of epilepsy and other neurological conditions. Reviews in Contemporary Pharmacotherapy 2004; 13: 1168.Google Scholar
Pellock, JM, Glauser, TA, Bebin, EM, Fountain, NB, Ritter, FJ, Coupez, RM, Shileds, WD. Pharmacokinetic study of levetiracetam in children. Epilepsia 2001; 42: 15741579.CrossRefGoogle ScholarPubMed
Rocamora, R, Wagner, K, Schulze-Bonhage, A. Levetiracetam reduces frequency and duration of epileptic activity in patients with refractory primary generalized epilepsy. Seizure 2006; 15: 428433.CrossRefGoogle ScholarPubMed
Shallcross, R, Bromley, RL, Irwin, B, Bonnett, LJ, Morrow, J, Baker, GA. Child development following in utero exposure. Levetiracetam vs sodium valproate. Neurology 2011; 76: 383389.CrossRefGoogle ScholarPubMed
Shorvon, SD, Lowenthal, A, Janz, D, Bielen, E, Loiseau, P; for the European Levetiracetam Study Group. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000; 41: 11791186.CrossRefGoogle ScholarPubMed
Specchio, LM, Gambardella, A, Giallonardo, AT, Michelucci, R, Specchio, N, Boero, G, La Neve, A. Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy. Epilepsy Research 2006; 71: 3239.CrossRefGoogle Scholar
St. Louis, EK, Gidal, BE, Henry, TR, Kaydanova, Y, Krumholz, A, McCabe, PH, Montouris, GD, Rosenfeld, WE, Smith, BJ, Stern, JM, Waterhouse, EJ, Schulz, RM, Garnett, WR, Bramley, T. Conversions between monotherapies in epilepsy: expert consensus. Epilepsy and Behavior 2007; 11: 222234.CrossRefGoogle ScholarPubMed
Striano, P, Coppola, A, Pezzella, M, Ciampa, C, Specchio, N, Ragona, F, Mancardi, MM, Gennaro, E, Beccaria, F, Capovilla, G, Rasmini, P, Besana, D, Coppola, GG, Elia, M, Granata, T, Vecchi, M, Vigevano, F, Viri, M, Gaggero, R, Striano, S, Zara, F. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology 2007; 69: 250254.CrossRefGoogle ScholarPubMed
von Stülpnagel, C, Kluger, G, Leiz, S, Holthausen, H. Levetiracetam as add-on therapy in different subgroups of “benign” idiopathic focal epilepsies in childhood. Epilepsy and Behavior 2010; 17: 193198.CrossRefGoogle ScholarPubMed
Westin, AA, Reimers, A, Helde, G, Nakken, KO, Brodtkorb, E. Serum concentration/dose ratio of levetiracetam before, during and after pregnancy. Seizure 2008; 17: 192198.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×